Announcements Trials
Browse Landscape

Status

Recruiting 2Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER_GOV 1OTHER 1

Study Type

Interventional 18Observational 5

Sponsor

Cancer Type

Thoracic 5

Conditions

Carcinoma, Non-Small-Cell Lung 4Resectable Non-small Cell Lung Cancer 1

Interventions

Blood Specimen Collection 31Sorafenib 29Nivolumab 29Bevacizumab 26Data Collection 24Observation 23palbociclib 22Sunitinib 22radium Ra 223 dichloride 20enzalutamide 18Rituximab 18Ipilimumab 16regorafenib 15Drug Therapy 15Trastuzumab 14Docetaxel 14ribociclib 12exemestane 12atezolizumab 12Standard of Care 12darolutamide 11apalutamide 11Leuprolide 11Capecitabine 11Afatinib 11Bortezomib 10Anastrozole 10trastuzumab deruxtecan 9pembrolizumab 9avelumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Observational × Platinum Compounds × Clear all
NCT05363319 2026-05-13

CEMI-LUNG

Regeneron Pharmaceuticals

Recruiting
500 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07141563 2026-01-07

A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC

Bristol-Myers Squibb

Completed
70 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07215962 2025-10-14

Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%

Bristol-Myers Squibb

Active not recruiting
300 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06169956 2024-04-18

NENI

Bristol-Myers Squibb

Recruiting
400 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

NCT05862194 2023-08-22

Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC

Yuhan Corporation

Completed
534 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡